Blenrep Euroopan unioni - suomi - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Darzalex Euroopan unioni - suomi - EMA (European Medicines Agency)

darzalex

janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. yhdessä bortetsomibin kanssa, talidomidin ja deksametasonin hoitoon aikuispotilailla, joilla on äskettäin diagnosoitu multippeli myelooma, jotka ovat oikeutettuja autologisen kantasolujen siirto. yhdessä lenalidomidin ja deksametasonin tai bortetsomibi ja deksametasoni, hoitoon aikuisille potilaille, joilla on multippeli myelooma, jotka ovat saaneet vähintään yhtä aiempaa hoitoa. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. monoterapiana aikuispotilaille, joilla oli uusiutunut ja refraktorinen multippeli myelooma, joiden aiempi hoito, mukana proteasomin estäjä ja immunomoduloivan aineen, ja jotka ovat osoittaneet taudin etenemistä viimeinen hoito. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Sarclisa Euroopan unioni - suomi - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastiset aineet - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Pepaxti Euroopan unioni - suomi - EMA (European Medicines Agency)

pepaxti

oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastiset aineet - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

OMNIPAQUE 200 mg I/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

omnipaque 200 mg i/ml injektioneste, liuos

amersham health as - iohexolum - injektioneste, liuos - 200 mg i/ml - joheksoli

Omnipaque 240 mg I/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

omnipaque 240 mg i/ml injektioneste, liuos

ge healthcare as - iohexol - injektioneste, liuos - 240 mg i/ml - joheksoli

Omnipaque 300 mg I/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

omnipaque 300 mg i/ml injektioneste, liuos

ge healthcare as - iohexol - injektioneste, liuos - 300 mg i/ml - joheksoli

Omnipaque 350 mg I/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

omnipaque 350 mg i/ml injektioneste, liuos

ge healthcare as - iohexol - injektioneste, liuos - 350 mg i/ml - joheksoli

Omnipaque 180 mg I/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

omnipaque 180 mg i/ml injektioneste, liuos

ge healthcare as - iohexol - injektioneste, liuos - 180 mg i/ml - joheksoli

Omnipaque 140 mg I/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

omnipaque 140 mg i/ml injektioneste, liuos

ge healthcare as - iohexol - injektioneste, liuos - 140 mg i/ml - joheksoli